BMGLNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends June 30
Basel Medical Group Ltd
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Nov 18, 2025
$4.05+0.10 (+2.53%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2023 to 2025
Net margin
-94.0%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +12.6% | – | – | – |
Returns and balance sheet
3 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2023 | FY2023 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | – | – | 1.31 | |
| Capex to revenue | – | – | 4.9% | |
| Diluted shares | – | – | 19M |
Cash use needs five years of cash flow figures
Basel Medical does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-10.64M SGD
- Cash generatingOperating cash flow above zero-4.04M SGD
- Return on assets improvedROA up on the prior year– → -65.2%
- Earnings backed by cashOperating cash flow above net income-4.04M SGD vs -10.64M SGD
- Less leverageLong-term debt to assets fell9.7% → 15.8%
- Better liquidityCurrent ratio rose2.26 → 1.31
- No dilutionShare count did not rise16M → 19M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → 0.69